CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$0.63 USD
+0.02 (2.46%)
Updated Sep 26, 2025 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CANF 0.63 +0.02(2.46%)
Will CANF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CANF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CANF
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know
Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
CANF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CANF
CANF forms Jack-in-the-box Bearish on September 26
Is CANF gaining bearish strength? New 52 Week Closing Low shows up after sliding 1.21%
New 52 Week Closing Low appears for CANF after 1.81% move
New 52 Week Closing Low appears for CANF after 0.87% move
Can-Fite BioPharma Reports H1 2025 Results and Updates